IA
CRDF icon

IFP Advisors’s Cardiff Oncology CRDF Stock Holding History

IFP Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.99K Buy
3,840
+3,835
+76,700% +$6.09K ﹤0.01% 3793
2026
Q1 		$8 Buy
+5
New +$10 ﹤0.01% 4977
2025
Q2 		– Hold
0
– – – 4730
2019
Q1 		– Sell
-7
Closed – – 2548
2018
Q4 		$0 Sell
7
-28
-80% -$128 ﹤0.01% 3577
2018
Q3 		$0 Hold
35
– – ﹤0.01% 3855
2018
Q2 		$0 Hold
35
– – ﹤0.01% 3901
2018
Q1 		$1K Hold
35
– – ﹤0.01% 3612
2017
Q4 		$1K Sell
35
-7
-17% -$310 ﹤0.01% 3663
2017
Q3 		$2K Hold
42
– – ﹤0.01% 3728
2017
Q2 		$4K Hold
42
– – ﹤0.01% 3488
2017
Q1 		$3K Sell
42
-41
-49% -$5.57K ﹤0.01% 3500
2016
Q4 		$13K Sell
83
-105
-56% -$24.5K ﹤0.01% 2738
2016
Q3 		$61K Buy
188
+32
+21% +$11.7K ﹤0.01% 1685
2016
Q2 		$51K Buy
+156
New +$53.7K ﹤0.01% 1748
2016
Q1 		– Sell
-7
Closed -$3K – 2554
2015
Q4 		$3K Buy
+7
New +$2.74K ﹤0.01% 3164

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IFP Advisors's CRDF Position: Q2 2026 in Review

IFP Advisors increased its Cardiff Oncology (CRDF) stake by 76,700% in Q2 2026, buying an estimated $6.09K and bringing the position to 3,840 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3793.

IFP Advisors first reported a position in CRDF in Q4 2015 and has held it in 14 quarters since. The position peaked at $61K in Q3 2016. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • IFP Advisors held 3,840 shares of Cardiff Oncology worth $4.99K as of Q2 2026.
  • IFP Advisors bought 3,835 Cardiff Oncology shares in Q2 2026, an estimated $6.09K.
  • Cardiff Oncology made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3793 holding.
  • IFP Advisors first reported a position in Cardiff Oncology in Q4 2015 and has held it in 14 quarters since.
  • IFP Advisors's Cardiff Oncology position peaked at $61K in Q3 2016.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.